These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

866 related items for PubMed ID: 11224490

  • 21. Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.
    Pontiggia L, Steiner B, Ulrichts H, Deckmyn H, Forestier M, Beer JH.
    Thromb Haemost; 2006 Dec; 96(6):774-80. PubMed ID: 17139372
    [Abstract] [Full Text] [Related]

  • 22. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
    Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF.
    J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
    [Abstract] [Full Text] [Related]

  • 23. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
    Matzdorff AC, Kühnel G, Kemkes-Matthes B, Pralle H, Voss R, Fareed J.
    J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
    [Abstract] [Full Text] [Related]

  • 24. Platelet-monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by Abciximab.
    Ray MJ, Walters DL, Bett JN, Cameron J, Wood P, Aroney CN.
    Int J Cardiol; 2005 May 25; 101(2):249-55. PubMed ID: 15882672
    [Abstract] [Full Text] [Related]

  • 25. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
    Giordano A, Musumeci G, D'Angelillo A, Rossini R, Zoccai GB, Messina S, Coscioni E, Romano S, Romano MF.
    Curr Drug Metab; 2016 May 25; 17(2):194-203. PubMed ID: 26652157
    [Abstract] [Full Text] [Related]

  • 26. Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonist and argatroban during in vitro extracorporeal circulation.
    Kanemitsu S, Nishikawa M, Onoda K, Shimono T, Shimpo H, Yazaki A, Tanaka K, Shiku H, Yada I.
    J Thorac Cardiovasc Surg; 2003 Aug 25; 126(2):428-35. PubMed ID: 12928640
    [Abstract] [Full Text] [Related]

  • 27. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
    Peter K, Schwarz M, Ylänne J, Kohler B, Moser M, Nordt T, Salbach P, Kübler W, Bode C.
    Blood; 1998 Nov 01; 92(9):3240-9. PubMed ID: 9787160
    [Abstract] [Full Text] [Related]

  • 28. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.
    Peter K, Kohler B, Straub A, Ruef J, Moser M, Nordt T, Olschewski M, Ohman ME, Kübler W, Bode C.
    Circulation; 2000 Sep 26; 102(13):1490-6. PubMed ID: 11004138
    [Abstract] [Full Text] [Related]

  • 29. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects.
    Abernethy DR, Pezzullo J, Mascelli MA, Frederick B, Kleiman NS, Freedman J.
    Clin Pharmacol Ther; 2002 Mar 26; 71(3):186-95. PubMed ID: 11907493
    [Abstract] [Full Text] [Related]

  • 30. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
    Peter K, Straub A, Kohler B, Volkmann M, Schwarz M, Kübler W, Bode C.
    Am J Cardiol; 1999 Sep 01; 84(5):519-24. PubMed ID: 10482148
    [Abstract] [Full Text] [Related]

  • 31. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin.
    Schneider DJ, Baumann PQ, Holmes MB, Taatjes DJ, Sobel BE.
    Thromb Haemost; 2001 Feb 01; 85(2):309-13. PubMed ID: 11246553
    [Abstract] [Full Text] [Related]

  • 32. Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abixicimab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters.
    Klinkhardt U, Kirchmaier CM, Westrup D, Breddin HK, Mahnel R, Graff J, Hild M, Harder S.
    Thromb Res; 2000 Feb 15; 97(4):201-7. PubMed ID: 10674406
    [Abstract] [Full Text] [Related]

  • 33. Surface-secreted von Willebrand factor mediates aggregation of ADP-activated platelets at moderate shear stress: facilitated by GPIb but controlled by GPIIb-IIIa.
    Frojmovic MM, Kasirer-Friede A, Goldsmith HL, Brown EA.
    Thromb Haemost; 1997 Mar 15; 77(3):568-76. PubMed ID: 9066012
    [Abstract] [Full Text] [Related]

  • 34. Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators.
    Graff J, Klinkhardt U, Harder S.
    Thromb Res; 2004 Mar 15; 113(5):295-302. PubMed ID: 15183041
    [Abstract] [Full Text] [Related]

  • 35. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ, Jordan RE, Mascelli MA.
    Thromb Haemost; 2001 Mar 15; 85(3):539-43. PubMed ID: 11307828
    [Abstract] [Full Text] [Related]

  • 36. Inhibition and reversal of platelet aggregation by alphaIIbbeta3 antagonists depends on the anticoagulant and flow conditions: differential effects of Abciximab and Lamifiban.
    Frojmovic M, Labarthe B, Legrand C.
    Br J Haematol; 2005 Nov 15; 131(3):348-55. PubMed ID: 16225655
    [Abstract] [Full Text] [Related]

  • 37. Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis.
    Abulencia JP, Tien N, McCarty OJ, Plymire D, Mousa SA, Konstantopoulos K.
    Arterioscler Thromb Vasc Biol; 2001 Jan 15; 21(1):149-56. PubMed ID: 11145947
    [Abstract] [Full Text] [Related]

  • 38. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
    Ilveskero S, Lassila R.
    Thromb Res; 2006 Jan 15; 117(3):291-7. PubMed ID: 15878612
    [Abstract] [Full Text] [Related]

  • 39. P-selectin expression on platelets determines size and stability of platelet aggregates.
    Merten M, Thiagarajan P.
    Circulation; 2000 Oct 17; 102(16):1931-6. PubMed ID: 11034941
    [Abstract] [Full Text] [Related]

  • 40. Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils.
    Caron A, Théorêt JF, Mousa SA, Merhi Y.
    J Cardiovasc Pharmacol; 2002 Aug 17; 40(2):296-306. PubMed ID: 12131559
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 44.